Walter J Storkus

USPTO Granted Patents = 16 (Patent Applications = 4)

CIPO Patents = 1

EPO Patents = 2 (Patent Applications = 2)

Average Co-Inventor Count = 2.3

ph-index = 5

Forward Citations = 100(Granted Patents)

Location History:

Pittsburgh, PA (US) (2016 - 2018)
Glenshaw, PA (US) (1999 - 2023)

Company Filing History:

15 out of 1,860

University of Pittsburgh

4. 1 out of 832,680

Other

patents

where one patent can have more than one assignee

Years Active: 1999-2023

Loading Chart...

16 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11787846 - EphA2 T-cell epitope agonists and uses therefore (2023-10-17),

2. 11723963 - Peptide analogs capable of enhancing stimulation of a glioma-specific CTL response (2023-08-15),

3. 10781240 - EPHA2 t-cell epitope agonists and uses therefore (2020-09-22),

4. 10434155 - Peptide analogs capable of enhancing stimulation of a glioma-specific CTL response (2019-10-08),

5. 10131699 - EphA2 T-cell epitope agonists and uses therefore (2018-11-20),

6. 9937250 - Immunogenic tumor associated stromal cell antigen peptides and methods of their use (2018-04-10),

7. 9675642 - Engineered dendritic cells and uses for the treatment of cancer (2017-06-13),

8. 9359402 - EphA2 T-cell epitope agonists and uses therefore (2016-06-07),

9. 9345770 - Immunogenic tumor associated stromal cell antigen peptides and methods of their use (2016-05-24),

10. 8859488 - Peptide analogs capable of enhancing stimulation of a glioma-specific CTL response (2014-10-14),

11. 8574584 - EphA2 T cell epitopes and uses therefor (2013-11-05),

12. 8114407 - EphA2 T-cell epitopes and uses therefor (2012-02-14),

13. 7612162 - Peptide analogs capable of enhancing stimulation of a glioma-specific CTL response (2009-11-03),

14. 7297337 - EphA2 T-cell epitopes and uses therefor (2007-11-20),

15. 6077519 - Methods for isolation and use of T cell epitopes eluted from viable (2000-06-20),

Title: Innovations by Inventor Walter J. Storkus

Introduction

Walter J. Storkus is a notable inventor based in Glenshaw, Pennsylvania, renowned for his contributions to biomedical innovations. With a remarkable portfolio of 16 patents, he has been instrumental in advancing therapeutic approaches, particularly in cancer treatment.

Latest Patents

Among his most recent inventions are the EphA2 T-cell epitope agonists, which include peptides derived from specific fragments of the human EphA2 protein. These epitopes play a critical role in immune assays such as ELISPOT, which can help quantify a patient's immune response to EphA2. The utility of these epitopes extends to modulating immune reactivity, particularly for cancers that overexpress EphA2, including renal cell carcinoma (RCC). Additionally, Storkus has worked on peptide analogs capable of enhancing the cytotoxic T lymphocyte response against gliomas. This invention focuses on peptides derived from the interleukin-13 receptor alpha-2, which are designed as vaccines formulated for both medical and veterinary use.

Career Highlights

Walter J. Storkus has garnered experience through his affiliations with prestigious institutions. His career includes significant contributions at the University of Pittsburgh and the University of Pittsburgh - of the Commonwealth System of Higher Education. His research aims to bridge the gap between basic science and clinical application, particularly in immunotherapy for cancer.

Collaborations

Storkus has collaborated with esteemed colleagues, including Michael Scott Kinch and Hideho Okada. Their collective expertise has furthered the development of innovative therapeutic strategies, combining their knowledge in immunology and oncology.

Conclusion

Walter J. Storkus exemplifies the spirit of innovation in the field of biomedical research. Through his extensive patent portfolio and collaborative efforts, he continues to impact cancer treatment positively, paving the way for future breakthroughs in immunotherapy. His work showcases the critical intersection of science and innovation in addressing complex health challenges.

This text is generated by artificial intelligence and may not be accurate.